Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27720005 | 0.80 | — | — | |
| SCHEMBL27702257 | 0.80 | — | — | |
| SCHEMBL8963604 | 0.78 | — | — | |
| SCHEMBL35600 | 0.77 | TDP1 (0.35) | TDP1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL967614 | 0.73 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9238524 | 0.72 | TDP1 (0.32) | TDP1 | |
| SCHEMBL27581314 | 0.72 | — | — | |
| SCHEMBL966579 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL27370094 | 0.71 | CHRNB2 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL27532901 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1111016-A | Non-specific reaction inhibitor | MITSUBISHI CHEM CORP (JP) | 1995-11-01 | — | — | CN | claimed |
| WO-2025085621-A1 | MULTIVALENT APTAMER-POLYMER CONJUGATES | VALITOR, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4507730-A2 | PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES | Valitor, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4508078-A2 | HUMANIZED MULTIVALENT PROTEIN CONJUGATES | Valitor, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20230405133-A1 | PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES | VALITOR, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230406916-A1 | HUMANIZED MULTIVALENT PROTEIN CONJUGATES | VALITOR, INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2023201335-A2 | PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES | VALITOR, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023201336-A2 | HUMANIZED MULTIVALENT PROTEIN CONJUGATES | VALITOR, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-108129431-B | Fluorenonaphthofuran derivative and application thereof | 北京鼎材科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-106770575-B | A kind of metabolism detection kit of the compound medicine for children's rhinitis | 戴伟利 | 2019-03-08 | — | — | CN | disclosed |
| US-9611357-B2 | Chemically modified dendrimers | GENZYME CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160096926-A1 | Chemically Modified Dendrimers | GENZYME CORPORATION | 2016-04-07 | — | — | US | disclosed |
| US-9283247-B2 | Chemically modified dendrimers | GENZYME CORPORATION (US) | 2016-03-15 | — | — | US | disclosed |
| US-20140186291-A1 | Chemically Modified Dendrimers | GENZYME CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-8658148-B2 | Chemically modified dendrimers | GENZYME CORPORATION (US) | 2014-02-25 | — | — | US | disclosed |
| US-20080317699-A1 | Chemically modified dendrimers | GENZYME CORPORATION | 2008-12-25 | — | — | US | disclosed |
| US-7186725-B2 | Anti-inflammatory compositions and methods | GENZYME CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040180871-A1 | Anti-inflammatory compositions and methods | GENZYME CORPORATION | 2004-09-16 | — | — | US | disclosed |
| WO-2004063181-A1 | UREA DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | GENZYME CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-0679892-B1 | Microparticle immunoassay reagents, sensitive and specific immunoassay reagents and immunoassay methods using these reagents | SERADYN INC (US) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186291-A1 | Chemically Modified Dendrimers | PAM, UACA, AADAC | TDP1 3106/4885CHRNB2 4439/4885CHRNB4 4616/4885 |
| US-20230405133-A1 | PURIFIED MULTIVALENT PROTEIN-HYALURONIC ACID POLYMER CONJUGATES | CD44, MSN, SIGLEC7 | TDP1 3567/4885CHRNB2 4349/4885CHRNB4 4395/4885 |
| US-20230406916-A1 | HUMANIZED MULTIVALENT PROTEIN CONJUGATES | FCGR2A, FCGR1A, FCGR3B | TDP1 2266/4885CHRNB2 2403/4885CHRNB4 2030/4885 |
| US-20080317699-A1 | Chemically modified dendrimers | PAM, UACA, AADAC | TDP1 3106/4885CHRNB2 4439/4885CHRNB4 4616/4885 |
| US-20040180871-A1 | Anti-inflammatory compositions and methods | CD4, LCP2, IL6 | TDP1 3643/4885CHRNB2 3536/4885CHRNB4 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.